Sugi Predict

Sugi Predict / Compounds / SCHEMBL2914561

SCHEMBL2914561

SCHEMBL2914561

NC(=O)CC1CNCCN1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A1 P30531 2/20 0.35
▸ GABRA5 P31644 2/20 0.35
▸ GABRB2 P47870 2/20 0.35
▸ SLC6A12 P48065 2/20 0.35
▸ SLC6A11 P48066 2/20 0.35
▸ SLC6A13 Q9NSD5 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ GABRR1 P24046 1/20 0.35
▸ GABRA4 P48169 1/20 0.35
▸ PARP1 P09874 2/20 0.33
▸ LTA4H P09960 1/20 0.31
▸ FDPS P14324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912294 0.88 KDM4E (0.41) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL2916214 0.82 GABRA5 (0.35) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL2917738 0.81 SLC6A1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL25154289 0.81 SLC6A1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL21315847 0.81 SLC6A1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL23802780 0.80 KDM4E (0.30) KDM4E
SCHEMBL23802896 0.80 KDM4E (0.30) KDM4E
Hydrochloric Acid SCHEMBL27835400 0.79 SLC6A11 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL27909011 0.79 SLC6A1 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Hydrochloric Acid SCHEMBL27795065 0.79 SLC6A11 (0.48) SLC6A1GABRA5GABRB2SLC6A12SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1100777-C N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2003-02-05 — — CN claimed
CN-1252799-A N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2000-05-10 — — CN claimed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
CN-111918651-B GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-01-30 — — CN disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 — — US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed
CN-1100777-C N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2003-02-05 — — CN disclosed
CN-1252799-A N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2000-05-10 — — CN disclosed
US-4766125-A N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia JANSSEN PHARMACEUTICA N.V. (BE) 1988-08-23 — — US disclosed
EP-0068544-B1 NOVEL N-ARYL-PIPERAZINEALKANAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1987-06-03 — — EP disclosed
EP-0068544-A2 Novel N-aryl-piperazinealkanamides JANSSEN PHARMACEUTICA N.V. (BE) 1983-01-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 SLC6A1 1251/4885GABRA5 2263/4885GABRB2 2357/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SLC6A1 3476/4885GABRA5 2406/4885GABRB2 3642/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 SLC6A1 1341/4885GABRA5 1691/4885GABRB2 3006/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS SLC6A1 4019/4885GABRA5 4379/4885GABRB2 4296/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC6A1 4019/4885GABRA5 4379/4885GABRB2 4296/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC6A1 4001/4885GABRA5 4242/4885GABRB2 3997/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS SLC6A1 4001/4885GABRA5 4242/4885GABRB2 3997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.